Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis
ConclusionsPD-1 blockade plus lenvatinib is effective and safe in routine practice. PD-L1 expression and CA19-9 level appear to predict the treatment efficacy.IDH1 mutations might indicate a better treatment response.Clinical trial registration: NCT03892577.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Bile Duct Cancer | Cancer | Cancer & Oncology | Chemotherapy | Cholangiocarcinoma | Clinical Trials | Genetics | Immunotherapy | Study | Toxicology